Video
Dr. Leblond Discusses Treatment After Relapse in CLL
Author(s):
Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.
Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.
For patients who relapse within 3 years after discontinuation of chemotherapy, BCR inhibitors or venetoclax (Venclexta) can be used.
Questions remain for patients who have late relapses, says Leblond. For these patients with relapses 4 or 5 years after initial therapy, BCR inhibitors can be used—but combinations of immunotherapy, chemotherapy, and BCR inhibitors also hold promise.
